🇺🇸 FDA
Pipeline program

Ryzodeg 100 units/mL FlexTouch solution for injection in pre-filled pen, IcoSema 700 U/mL + 2 mg/mL PDS290

NN1535-8377

Phase 3 small_molecule active

Quick answer

Ryzodeg 100 units/mL FlexTouch solution for injection in pre-filled pen, IcoSema 700 U/mL + 2 mg/mL PDS290 for Type 2 diabetes is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Novo Nordisk A/S
Indication
Type 2 diabetes
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials